Functional proteomics strategy for validation of protein kinase inhibitors reveals new targets for a TBB-derived inhibitor of protein kinase CK2

Journal of Proteomics

Volumn 81, Issue , 2013, Pages 70-79

  Gyenis, Laszlo ^a   Kuś, Agnieszka ^b   Bretner, Maria ^b,c   Litchfield, David W ^a  

^a WESTERN UNIVERSITY   (Canada)

^b WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

^c INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

Author keywords

Chemoproteomics; CK2; Inhibitor profiling; Mass spectrometry; Protein kinase inhibitors; TBB

Indexed keywords

CASEIN KINASE II INHIBITOR; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN KINASE INHIBITOR; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION (PARAMETERS); CYTOLYSIS; DRUG BIOAVAILABILITY; DRUG STRUCTURE; PRIORITY JOURNAL; PROTEOMICS; VALIDATION STUDY;

CASEIN KINASE II; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HUMANS; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTEOMICS; SUBSTRATE SPECIFICITY;

EID: 84878014269     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.09.017     Document Type: Article

References (60)

1. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
2. Johnson S.A., Hunter T. Kinomics: methods for deciphering the kinome. Nat Methods 2005, 2:17-25.
3. Bettayeb K., Tirado O.M., Marionneau-Lambot S., Ferandin Y., Lozach O., Morris J.C., et al. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res 2007, 67:8325-8334.
4. van Oosterom A.T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421-1423.
5. Bantscheff M., Eberhard D., Abraham Y., Bastuck S., Boesche M., Hobson S., et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007, 25:1035-1044.
6. Jabbour E., Cortes J.E., Ghanem H., O'Brien S., Kantarjian H.M. Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther 2008, 8:99-110.
7. Quintas-Cardama A., Kantarjian H., Cortes J.E. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007, 6:834-848.
8. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
9. Litchfield D.W. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 2003, 369:1-15.
10. Gyenis L., Litchfield D.W. The emerging CK2 interactome: insights into the regulation and functions of CK2. Mol Cell Biochem 2008, 316:5-14.
11. Olsten M.E., Weber J.E., Litchfield D.W. CK2 interacting proteins: emerging paradigms for CK2 regulation?. Mol Cell Biochem 2005, 274:115-124.
12. Meggio F., Pinna L.A. One-thousand-and-one substrates of protein kinase CK2?. FASEB J 2003, 17:349-368.
13. Yenice S., Davis A.T., Goueli S.A., Akdas A., Limas C., Ahmed K. Nuclear casein kinase 2 (CK-2) activity in human normal, benign hyperplastic, and cancerous prostate. Prostate 1994, 24:11-16.
14. Landesman-Bollag E., Romieu-Mourez R., Song D.H., Sonenshein G.E., Cardiff R.D., Seldin D.C. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 2001, 20:3247-3257.
15. Daya-Makin M., Sanghera J.S., Mogentale T., Lipp M., Parchomchuk J., Hogg J., et al. Activation of a tumour-associated protein kinase (p40TAK) and casein kinase II in human squamous cell carcinomas and adenocarcinomas of the lung. Cancer Res 1994, 54:2262-2268.
16. Stalter G., Siemer S., Becht E., Ziegler M., Remberger K., Issinger O.G. Asymmetric expression of protein kinase CK2 subunits in human kidney tumors. Biochem Biophys Res Commun 1994, 202:141-147.
17. Faust R.A., Gapany M., Tristani P., Davis A., Adams G.L., Ahmed K. Elevated protein kinase CK2 activity in chromatin of head and neck tumors: association with malignant transformation. Cancer Lett 1996, 101:31-35.
18. Ahmad K.A., Wang G., Unger G., Slaton J., Ahmed K. Protein kinase CK2-a key suppressor of apoptosis. Adv Enzyme Regul 2008, 48:179-187.
19. Wang G., Ahmad K.A., Harris N.H., Ahmed K. Impact of protein kinase CK2 on inhibitor of apoptosis proteins in prostate cancer cells. Mol Cell Biochem 2008, 316:91-97.
20. Duncan J.S., Turowec J.P., Vilk G., Li S.S., Gloor G.B., Litchfield D.W. Regulation of cell proliferation and survival: convergence of protein kinases and caspases. Biochim Biophys Acta 2010, 1804:505-510.
21. Duncan J.S., Turowec J.P., Duncan K.E., Vilk G., Wu C., Luscher B., et al. A peptide-based target screen implicates the protein kinase CK2 in the global regulation of caspase signaling. Sci Signal 2011, 4:ra30.
22. Turowec J.P., Duncan J.S., Gloor G.B., Litchfield D.W. Regulation of caspase pathways by protein kinase CK2: identification of proteins with overlapping CK2 and caspase consensus motifs. Mol Cell Biochem 2011, 356:159-167.
23. Pierre F., Chua P.C., O'Brien S.E., Siddiqui-Jain A., Bourbon P., Haddach M., et al. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol Cell Biochem 2011, 356:37-43.
24. Siddiqui-Jain A., Drygin D., Streiner N., Chua P., Pierre F., O'Brien S.E., et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 2010, 70:10288-10298.
25. Moucadel V., Prudent R., Sautel C.F., Teillet F., Barette C., Lafanechere L., et al. Antitumoral activity of allosteric inhibitors of protein kinase CK2*. Oncotarget 2011, 2:997-1010.
26. Pagano M.A., Bain J., Kazimierczuk Z., Sarno S., Ruzzene M., Di Maira G., et al. The selectivity of inhibitors of protein kinase CK2: an update. Biochem J 2008, 415:353-365.
27. Sarno S., Papinutto E., Franchin C., Bain J., Elliott M., Meggio F., et al. ATP site-directed inhibitors of protein kinase CK2: an update. Curr Top Med Chem 2011, 11:1340-1351.
28. Sarno S., Reddy H., Meggio F., Ruzzene M., Davies S.P., Donella-Deana A., et al. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett 2001, 496:44-48.
29. Cozza G., Mazzorana M., Papinutto E., Bain J., Elliott M., di Maira G., et al. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. Biochem J 2009, 421:387-395.
30. Prudent R., Moucadel V., Laudet B., Barette C., Lafanechère L., Hasenknopf B., et al. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2. Chem Biol 2008, 15:683-692.
31. Bach S., Knockaert M., Reinhardt J., Lozach O., Schmitt S., Baratte B., et al. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005, 280:31208-31219.
32. Duncan J.S., Gyenis L., Lenehan J., Bretner M., Graves L.M., Haystead T.A., et al. An unbiased evaluation of CK2 inhibitors by chemo-proteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Mol Cell Proteomics 2008, 7:1077-1088.
33. Gyenis L., Duncan J.S., Turowec J.P., Bretner M., Litchfield D.W. Unbiased functional proteomics strategy for protein kinase inhibitor validation and identification of bona fide protein kinase substrates: application to identification of EEF1D as a substrate for CK2. J Proteome Res 2011, 10:4887-4901.
34. Duncan J.S., Haystead T.A., Litchfield D.W. Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP. Methods Mol Biol 2012, 795:119-134.
35. Knight Z.A., Shokat K.M. Features of selective kinase inhibitors. Chem Biol 2005, 12:621-637.
36. Ruzzene M., Penzo D., Pinna L.A. Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 2002, 364:41-47.
37. Fritz G., Issinger O.G., Olsen B.B. Selectivity analysis of protein kinase CK2 inhibitors DMAT, TBB and resorufin in cisplatin-induced stress responses. Int J Oncol 2009, 35:1151-1157.
38. Gratz A., Gotz C., Jose J. A FRET-based microplate assay for human protein kinase CK2, a target in neoplastic disease. J Enzyme Inhib Med Chem 2010, 25:234-239.
39. Hessenauer A., Schneider C.C., Gotz C., Montenarh M. CK2 inhibition induces apoptosis via the ER stress response. Cell Signal 2011, 23:145-151.
40. Litchfield D.W., Lozeman F.J., Cicirelli M.F., Harrylock M., Ericsson L.H., Piening C.J., et al. Phosphorylation of the beta subunit of casein kinase II in human A431 cells. Identification of the autophosphorylation site and a site phosphorylated by p34cdc2. J Biol Chem 1991, 266:20380-20389.
41. Litchfield D.W., Luscher B., Lozeman F.J., Eisenman R.N., Krebs E.G. Phosphorylation of casein kinase II by p34cdc2 in vitro and at mitosis. J Biol Chem 1992, 267:13943-13951.
42. Wasik R., Lebska M., Felczak K., Poznanski J., Shugar D. Relative role of halogen bonds and hydrophobic interactions in inhibition of human protein kinase CK2alpha by tetrabromobenzotriazole and some C5-substituted analogues. J Phys Chem B 2010, 114:10601-10611.
43. Bischoff N., Raaf J., Olsen B., Bretner M., Issinger O.G., Niefind K. Enzymatic activity with an incomplete catalytic spine: insights from a comparative structural analysis of human CK2alpha and its paralogous isoform CK2alpha'. Mol Cell Biochem 2011, 356:57-65.
44. Godl K., Wissing J., Kurtenbach A., Habenberger P., Blencke S., Gutbrod H., et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci U S A 2003, 100:15434-15439.
45. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979, 76:4350-4354.
46. Pagano M.A., Poletto G., Di Maira G., Cozza G., Ruzzene M., Sarno S., et al. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem 2007, 8:129-139.
47. Gerber S.H., Rizo J., Sudhof T.C. Role of electrostatic and hydrophobic interactions in Ca(2+)-dependent phospholipid binding by the C(2)A-domain from synaptotagmin I. Diabetes 2002, 51(Suppl. 1):S12-S18.
48. Battistutta R., De Moliner E., Sarno S., Zanotti G., Pinna L.A. Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole. Protein Sci 2001, 10:2200-2206.
49. Sarno S., Moro S., Meggio F., Zagotto G., Dal Ben D, Ghisellini P, et al. Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol Ther 2002, 93:159-168.
50. Battistutta R., Mazzorana M., Sarno S., Kazimierczuk Z., Zanotti G., Pinna L.A. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole. Chem Biol 2005, 12:1211-1219.
51. Brehmer D., Godl K., Zech B., Wissing J., Daub H. Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol Cell Proteomics 2004, 3:490-500.
52. Brehmer D., Greff Z., Godl K., Blencke S., Kurtenbach A., Weber M., et al. Cellular targets of gefitinib. Cancer Res 2005, 65:379-382.
53. Geiger T., Wehner A., Schaab C., Cox J., Mann M. Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins. Mol Cell Proteomics 2012, 11(M111):014050.
54. Guarnieri M.T., Zhang L., Shen J., Zhao R. The Hsp90 inhibitor radicicol interacts with the ATP-binding pocket of bacterial sensor kinase PhoQ. J Mol Biol 2008, 379:82-93.
55. Janeczko M., Orzeszko A., Kazimierczuk Z., Szyszka R., Baier A. CK2alpha and CK2alpha' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Eur J Med Chem 2012, 47:345-350.
56. Traut T.W. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 1994, 140:1-22.
57. Kramerov A.A., Golub A.G., Bdzhola V.G., Yarmoluk S.M., Ahmed K., Bretner M., et al. Treatment of cultured human astrocytes and vascular endothelial cells with protein kinase CK2 inhibitors induces early changes in cell shape and cytoskeleton. Mol Cell Biochem 2011, 349:125-137.
58. Niefind K., Pütter M., Guerra B., Issinger O.G., Schomburg D. GTP plus water mimic ATP in the active site of protein kinase CK2. Nat Struct Biol 1999, 6:1100-1103.
59. Ferguson A.D., Sheth P.R., Basso A.D., Paliwal S., Gray K., Fischmann T.O., et al. Structural basis of CX-4945 binding to human protein kinase CK2. FEBS Lett 2011, 585:104-110.
60. Zien P., Duncan J.S., Skierski J., Bretner M., Litchfield D.W., Shugar D. Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2. Biochim Biophys Acta 2005, 1754:271-280.